Midcareer Investigator Award

职业生涯中期研究员奖

• 批准号: 8383117
• 负责人: MATTHEW RAYMOND SMITH
• 金额: $ 18.6万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-05 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8383117
• 关键词: Acetates; Adverse effects; Anabolism; Androgen Receptor; Androgens; Area; Award; Biological Markers; Body Composition; Bone Density; Cancer Center; Cancer Survivorship; Castration; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Commit; Development; Dose; Funding; General Hospitals; Goals; Heterogeneity; Lead; Malignant Neoplasms; Malignant neoplasm of prostate; Massachusetts; Medical Oncologist; Mentors; Metabolic; Metabolism; Metastatic Neoplasm to the Bone; Metastatic Prostate Cancer; Methodology; Microfluidics; Molecular; New Agents; Peer Review; Peer Review Grants; Pharmaceutical Preparations; Prevention; Productivity; Receptor Signaling; Research; Research Activity; Research Personnel; Resistance; Signal Pathway; Time; Training; Vascular Endothelial Growth Factor Receptor; abiraterone; catalyst; clinical care; deprivation; design; drug mechanism; effective therapy; improved; inhibitor/antagonist; male health; men; neoplastic cell; next generation; novel; patient oriented research; prevent; programs; resistance mechanism; response; small molecule; survivorship; therapy development

DESCRIPTION (provided by applicant): The broad long-term objectives of this K24 renewal are to enhance the research productivity of the candidate and to increase the pool of well-trained clinical researchers who can conduct patient-oriented research, compete for peer reviewed grants, and mentor the next generation of clinical investigators. The Specific Aims are to: (1) develop and expand the candidate's capabilities in patient-oriented research, and (2) mentor new investigators in patient-oriented research. The candidate is a medical oncologist with particular expertise in prostate cancer. He has a strong record of patient-oriented research, independent peer-reviewed funding, and effective mentoring. The candidate's clinical research program focuses on prostate cancer survivorship and the prevention and treatment of bone metastases. In the first 5 years of this K24, the candidate has helped improve the clinical care for men with prostate cancer by identifying previously unrecognized harms of androgen deprivation therapy and by developing effective new treatments for prostate cancer. In the first five years of this K24, the candidate has also successfully mentored 10 junior investigators in patient-oriented research. This K24 renewal coincides with important new directions in the candidate's research program. The research program has been developed and expanded around three research themes: survivorship, biomarkers, and novel therapy. This K24 renewal also coincides with the identification of three new mentees and planned expansion of mentoring responsibilities at Massachusetts General Hospital, Dana Farber Harvard Cancer Center, and the Harvard Catalyst. The support of this K24 renewal is essential to provide the candidate with the protected time necessary to develop and expand patient-oriented research and mentoring. PUBLIC HEALTH RELEVANCE: Prostate cancer is a major cause of suffering and death in men worldwide. The broad long-term objective of this proposal is to improve the health of men with prostate cancer by preventing the unintended side-effects of treatment and by developing new more effective treatments. These goals will be accomplished by developing and expanding the candidate's patient-oriented research program in prostate cancer and by training new investigators in patient-oriented research.

描述（由申请人提供）：本次K24更新的广泛长期目标是提高候选人的研究生产力，并增加训练有素的临床研究人员的数量，他们可以进行以患者为导向的研究，竞争同行评审赠款，并指导下一代临床研究者。具体目标是：（1）发展和扩大候选人在以患者为导向的研究中的能力，以及（2）指导新的研究人员以患者为导向的研究。 候选人是一名医学肿瘤学家，在前列腺癌方面具有特殊的专业知识。他在以病人为导向的研究、独立的同行评审资金和有效的指导方面有着良好的记录。候选人的临床研究计划侧重于前列腺癌的生存率和骨转移的预防和治疗。在K24的前5年，候选人通过识别雄激素剥夺疗法的先前未被认识到的危害和开发有效的前列腺癌新疗法，帮助改善了前列腺癌男性的临床护理。在K24的前五年，候选人还成功地指导了10名以患者为导向的研究初级研究人员。 K24的更新与候选人研究计划的重要新方向相吻合。该研究计划围绕三个研究主题进行开发和扩展：生存，生物标志物和新疗法。K24的更新也恰逢马萨诸塞州总医院、哈佛癌症中心和哈佛催化剂确定了三名新的学员，并计划扩大辅导职责。对K24更新的支持对于为候选人提供发展和扩大以患者为导向的研究和指导所需的受保护时间至关重要。 公共卫生相关性：前列腺癌是全世界男性痛苦和死亡的主要原因。该提案的广泛长期目标是通过预防治疗的意外副作用和开发新的更有效的治疗方法来改善前列腺癌患者的健康。这些目标将通过发展和扩大候选人的前列腺癌患者为导向的研究计划，并通过培训新的研究人员在患者为导向的研究。